Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Clifford Kim is active.

Publication


Featured researches published by Clifford Kim.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus

Clifford Kim; Sarah A. Wilcox-Adelman; Yasuyo Sano; Wei-Jen Tang; R. J. Collier; Junsoo Park

Bacillus anthracis, the etiologic agent of anthrax, avoids immune surveillance and commandeers host macrophages as a vehicle for lymphatic spreading. Here, we show that B. anthracis edema toxin (ET), via its adenylyl cyclase activity, dramatically increases the motility of infected macrophages and the expression of vascular endothelial growth factor. The transcription factor CREB and the syndecan-1 gene, a CREB target, play crucial roles in ET-induced macrophage migration. These molecular and cellular responses occur in macrophages engaged in antiinflammatory G protein-coupled receptor activation, thus illustrating a common signaling circuitry controlling resolution of inflammation and host cell hijacking by B. anthracis.


Journal of Biological Chemistry | 2015

Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1)

Pratap Karki; Clifford Kim; Keisha Smith; Deok Soo Son; Michael Aschner; Eunsook Lee

Background: The mechanism for transcriptional regulation of EAAT1 remains to be elucidated. Results: EGF-activated NF-κB is a positive regulator of EAAT1, whereas manganese-activated YY1, with HDACs acting as co-repressors, is a negative regulator. Conclusion: NF-κB and YY1 are two critical transcriptional regulators of EAAT1. Significance: Identifying the molecular targets of EAAT1 regulation is crucial to develop therapeutics against neurological disorders associated with impairment of EAAT1. Astrocytic glutamate transporter excitatory amino acid transporter (EAAT) 1, also known as glutamate aspartate transporter (GLAST) in rodents, is one of two glial glutamate transporters that are responsible for removing excess glutamate from synaptic clefts to prevent excitotoxic neuronal death. Despite its important role in neurophysiological functions, the molecular mechanisms of EAAT1 regulation at the transcriptional level remain to be established. Here, we report that NF-κB is a main positive transcription factor for EAAT1, supported by the following: 1) EAAT1 contains two consensus sites for NF-κB, 2) mutation of NF-κB binding sites decreased EAAT1 promoter activity, and 3) activation of NF-κB increased, whereas inhibition of NF-κB decreased EAAT1 promoter activity and mRNA/protein levels. EGF increased EAAT1 mRNA/protein levels and glutamate uptake via NF-κB. The transcription factor yin yang 1 (YY1) plays a role as a critical negative regulator of EAAT1, supported by the following: 1) the EAAT1 promoter contains multiple consensus sites for YY1, 2) overexpression of YY1 decreased EAAT1 promoter activity and mRNA/protein levels, and 3) knockdown of YY1 increased EAAT1 promoter activity and mRNA/protein levels. Manganese decreased EAAT1 expression via YY1. Epigenetic modifiers histone deacetylases (HDACs) served as co-repressors of YY1 to further decrease EAAT1 promoter activity, whereas inhibition of HDACs reversed manganese-induced decrease of EAAT1 expression. Taken together, our findings suggest that NF-κB is a critical positive regulator of EAAT1, mediating the stimulatory effects of EGF, whereas YY1 is a negative regulator of EAAT1 with HDACs as co-repressors, mediating the inhibitory effects of manganese on EAAT1 regulation.


Eye and Brain | 2016

Revisiting the mouse model of oxygen-induced retinopathy

Clifford Kim; Patricia A. D'Amore; Kip M. Connor

Abnormal blood vessel growth in the retina is a hallmark of many retinal diseases, such as retinopathy of prematurity (ROP), proliferative diabetic retinopathy, and the wet form of age-related macular degeneration. In particular, ROP has been an important health concern for physicians since the advent of routine supplemental oxygen therapy for premature neonates more than 70 years ago. Since then, researchers have explored several animal models to better understand ROP and retinal vascular development. Of these models, the mouse model of oxygen-induced retinopathy (OIR) has become the most widely used, and has played a pivotal role in our understanding of retinal angiogenesis and ocular immunology, as well as in the development of groundbreaking therapeutics such as anti-vascular endothelial growth factor injections for wet age-related macular degeneration. Numerous refinements to the model have been made since its inception in the 1950s, and technological advancements have expanded the use of the model across multiple scientific fields. In this review, we explore the historical developments that have led to the mouse OIR model utilized today, essential concepts of OIR, limitations of the model, and a representative selection of key findings from OIR, with particular emphasis on current research progress.


The FASEB Journal | 2016

The alternative complement pathway aids in vascular regression during the early stages of a murine model of proliferative retinopathy

Clifford Kim; Kaylee E. Smith; Alexandra Castillejos; Daniel Diaz-Aguilar; Magali Saint-Geniez; Kip M. Connor

Proliferative retinopathic diseases often progress in 2 phases: initial regression of retinal vasculature (phase 1) followed by subsequent neovascularization (NV) (phase 2). The immune system has been shown to aid in vascular pruning in such retinopathies; however, little is known about the role of the alternative complement pathway in the initial vascular regression phase. Using a mouse model of oxygen‐induced retinopathy (OIR), we observed that alternative complement pathway‐deficient mice (Fb–/–) exhibited a mild decrease in vascular loss at postnatal day (P)8 compared with age‐ and strain‐matched controls (P = 0.035). Laser capture microdissection was used to isolate the retinal blood vessels. Expression of the complement inhibitors Cd55 and Cd59 was significantly decreased in blood vessels isolated from hyperoxic retinas compared with those from normoxic control mice. Vegf expression was measured at P8 and found to be significantly lower in OIR mice than in normoxic control mice (P = 0.0048). Further examination of specific Vegf isoform expression revealed a significant decrease in Vegf120 (P= 0.00032) and Vegf188 (P= 0.0092). In conjunction with the major modulating effects of Vegf during early retinal vascular development, our data suggest a modest involvement of the alternative complement pathway in targeting vessels for regression in the initial vaso‐obliteration stage of OIR.—Kim, C., Smith, K. E., Castillejos, A., Diaz‐Aguilar, D., Saint‐Geniez, M., Connor, K. M., The alternative complement pathway aids in vascular regression during the early stages of a murine model of proliferative retinopathy. FASEB J. 30, 1300–1305 (2016). www.fasebj.org


Proceedings of the National Academy of Sciences of the United States of America | 2017

Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization

Eiichi Hasegawa; Saori Inafuku; Lama Mulki; Yoko Okunuki; Ryoji Yanai; Kaylee E. Smith; Clifford Kim; Garrett Klokman; Diane R. Bielenberg; Narender Puli; John R. Falck; Deeba Husain; Joan W. Miller; Matthew L. Edin; Darryl C. Zeldin; Kin Sing Stephen Lee; Bruce D. Hammock; Wolf Hagen Schunck; Kip M. Connor

Significance Abnormal blood vessel growth occurs in many common diseases, from cancers and cardiovascular diseases to ocular conditions like age-related macular degeneration (AMD) and is thus a major target of many recent treatment approaches. Long-chain polyunsaturated fatty acids are of significant interest in this context, since bioactive lipid metabolites derived from this pathway have been shown to be potent regulators of inflammation and angiogenesis. Our study has identified key compounds of the cytochrome P450 metabolic pathway that are responsible for resolving abnormal vascular growth in AMD, which work in part by modulating the recruitment of inflammatory immune cells. We believe these findings have significant therapeutic implications not only for AMD but also for other inflammatory disorders. Age-related macular degeneration (AMD) is the most common cause of blindness for individuals age 50 and above in the developed world. Abnormal growth of choroidal blood vessels, or choroidal neovascularization (CNV), is a hallmark of the neovascular (wet) form of advanced AMD and leads to significant vision loss. A growing body of evidence supports a strong link between neovascular disease and inflammation. Metabolites of long-chain polyunsaturated fatty acids derived from the cytochrome P450 (CYP) monooxygenase pathway serve as vital second messengers that regulate a number of hormones and growth factors involved in inflammation and vascular function. Using transgenic mice with altered CYP lipid biosynthetic pathways in a mouse model of laser-induced CNV, we characterized the role of these lipid metabolites in regulating neovascular disease. We discovered that the CYP-derived lipid metabolites epoxydocosapentaenoic acids (EDPs) and epoxyeicosatetraenoic acids (EEQs) are vital in dampening CNV severity. Specifically, overexpression of the monooxygenase CYP2C8 or genetic ablation or inhibition of the soluble epoxide hydrolase (sEH) enzyme led to increased levels of EDP and EEQ with attenuated CNV development. In contrast, when we promoted the degradation of these CYP-derived metabolites by transgenic overexpression of sEH, the protective effect against CNV was lost. We found that these molecules work in part through their ability to regulate the expression of key leukocyte adhesion molecules, on both leukocytes and endothelial cells, thereby mediating leukocyte recruitment. These results suggest that CYP lipid signaling molecules and their regulators are potential therapeutic targets in neovascular diseases.


Frontiers in Aging Neuroscience | 2018

The Complement System Is Critical in Maintaining Retinal Integrity during Aging

Ryo Mukai; Yoko Okunuki; Deeba Husain; Clifford Kim; John D. Lambris; Kip M. Connor

The complement system is a key component of innate immunity comprised of soluble components that form a proteolytic cascade leading to the generation of effector molecules involved in cellular clearance. This system is highly activated not only under general inflammatory conditions such as infections, collagen diseases, nephritis, and liver diseases, but also in focal ocular diseases. However, little is known about the role of the complement system in retinal homeostasis during aging. Using young (6-week-old) and adult (6-month-old) mice in wild type (C57BL/6) and complement knockout strains (C1q−/−, Mbl a/c−/−, Fb−/−, C3−/−, and C5−/−), we compared amplitudes of electroretinograms (ERG) and thicknesses of retinal layers in spectral domain optical coherence tomography between young and adult mice. The ERG amplitudes in adult mice were significantly decreased (p < 0.001, p < 0.0001) compared to that of young mice in all complement knockout strains, and there were significant decreases in the inner nuclear layer (INL) thickness in adult mice compared to young mice in all complement knockout strains (p < 0.0001). There were no significant differences in ERG amplitude or thickness of the INL between young and adult control mice. These data suggest that the complement system plays an important role in maintaining normal retinal integrity over time.


Investigative Ophthalmology & Visual Science | 2017

Cytochrome P450 monooxygenase lipid metabolites regulate choroidal neovascularization in the eye: contribution of the soluble epoxide hydrolase.

Kip M. Connor; Saori Inafuku; Clifford Kim; Deeba Husain; Joan W. Miller; Eiichi Hasegawa


Investigative Ophthalmology & Visual Science | 2017

The Complement System is required in maintaining retinal function

Ryo Mukai; Yoko Okunuki; Garrett Klokman; Saori Inafuku; Clifford Kim; Dongho Park; Deeba Husain; Kip M. Connor


Investigative Ophthalmology & Visual Science | 2017

Cytochrome P450 lipid metabolites alter leukocyte kinetics in a mouse model of choroidal inflammation

Clifford Kim; Eiichi Hasegawa; Saori Inafuku; Deeba Husain; Joan W. Miller; Kip M. Connor


Investigative Ophthalmology & Visual Science | 2016

The role of microglial expression of microRNA-155 on a murine model of retinal detachment

Yoko Okunuki; Eiichi Hasegawa; Ryo Mukai; Clifford Kim; Garrett Klokman; Saori Inafuku; Kip M. Connor

Collaboration


Dive into the Clifford Kim's collaboration.

Top Co-Authors

Avatar

Kip M. Connor

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Deeba Husain

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Eiichi Hasegawa

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Yoko Okunuki

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joan W. Miller

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Kaylee E. Smith

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar

Ryo Mukai

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alexandra Castillejos

Massachusetts Eye and Ear Infirmary

View shared research outputs
Researchain Logo
Decentralizing Knowledge